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Abstract: Species differences in physiology and unique active human metabolites contribute 
to the limited predictive value of preclinical rodent models for many central nervous system 
(CNS) drugs. In order to explore possible drivers for this translational disconnect, we devel-
oped a computer model of a dopaminergic synapse that simulates the competition among three 
agents and their binding to pre- and postsynaptic receptors, based on the affinities for their 
targets and their actual   concentrations. The model includes presynaptic autoreceptor effects 
on neurotransmitter release and modulation by presynaptic firing frequency and is calibrated 
with actual experimental data on free dopamine levels in the striatum of the rodent and the 
primate. Using this model, we simulated the postsynaptic dopamine D2 receptor activation 
levels of bifeprunox and aripiprazole, two relatively similar dopamine D2 receptor agonists. 
The results indicate a substantial difference in dose–response for the two compounds when 
applying primate calibration parameters as opposed to rodent calibration parameters. In addi-
tion, when introducing the major human and rodent metabolites of aripiprazole with their 
specific pharmacological activities, the model predicts that while bifeprunox would result 
in a higher postsynaptic D2 receptor antagonism in the rodent, aripiprazole would result in 
a higher D2 receptor antagonism in the primate model. Furthermore, only the highest dose 
of aripiprazole, but not bifeprunox, reaches postsynaptic functional D2 receptor antagonism 
similar to 4 mg haloperidol in the primate model. The model further identifies a limited opti-
mal window of functionality for dopamine D2 receptor partial agonists. These results suggest 
that computer modeling of key CNS processes, using well-validated calibration paradigms, 
can increase the predictive value in the clinical setting of preclinical animal model outcomes.
Keywords: dopamine antagonism, partial agonist, antipsychotics, computer simulation
Introduction
All currently marketed drugs in schizophrenia reduce the effects of the   dopaminergic 
striatal pathological hyperactivity by either directly or indirectly reducing the 
  activity of the postsynaptic D2 receptor.1 Recently, partial D2 receptor agonists have 
been proposed as a therapeutic approach. Their clinical efficacy is hypothesized to 
be dependent both on the stimulation of presynaptic D2 autoreceptors that reduce Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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  synaptic dopamine (DA) release and on the substitution 
of a full agonist (dopamine) with a partial agonist, with 
both effects being functionally equivalent to a postsynaptic 
D2 receptor block. This is an interesting approach as recent 
imaging studies in an at-risk for mental state cohorts sug-
gest a pre-synaptic pathology in schizophrenia patients.2 
Therefore, drugs acting on presynaptic D2 autoreceptors are 
supposed to act more closely to the actual pathology. Despite 
a substantial amount of research, only one partial agonist, 
aripiprazole, has shown successful clinical efficacy,3 while the 
clinical effect of bifeprunox,4 a partial agonist very similar to 
aripiprazole, is much more limited, leading to its premature 
clinical development halt. This suggests that it is difficult to 
identify the correct range of pharmacology parameters for 
partial agonism.
Because partial agonists at the postsynaptic receptor tend 
to counterbalance somewhat the effect at the presynaptic 
receptor, it is crucial to obtain an optimal balance between 
binding affinity and potency. In addition, increasing evidence 
suggests a substantial difference in quantitative biologi-
cal parameters between rodents and primates in key brain 
areas important for psychiatric diseases. For instance, the 
coupling of presynaptic dopamine D2 autoreceptor to DA 
release in striatal synapses is lower in primates5 than that in 
rodents.6 This difference can have important consequences 
for the effect of antipsychotics in humans in the treatment 
of schizophrenia.
Detailed in vitro studies7 show a small difference between 
aripiprazole and bifeprunox with regard to binding   affinity 
and maximal partial agonist effect. The question arises 
whether this small difference could actually lead to substan-
tially different functional antagonism at the postsynaptic 
D2 receptor, which drives a large part of the clinical response.8 
Because bifeprunox has been shown to be equivalent to, if 
not better than, aripiprazole in preclinical animal models,9 
the ability to estimate more quantitatively the global effect 
in a humanized situation becomes mandatory.
In order to explore these important questions, we devel-
oped a computer model of the striatal dopaminergic synapse, 
which includes the physiology of time-dependent   presynaptic 
autoreceptor activation and its subsequent modulation 
of DA release. The model allows for different presynaptic 
firing regimens, the effect of facilitation and depression on 
DA release, and simulates the competition between DA and 
up to three different agents for the same binding site, depen-
dent on their affinity and functionality. Our intention was to 
develop a model that focuses on the competition between 
endogenous DA and other agents and takes into account the 
modulation of free DA by firing frequencies and presynaptic 
mechanisms that is based on a large population of molecules. 
This article illustrates how calibration of this model with 
experimental data from rodents can lead to different con-
clusions, as compared to the calibration with experimental 
primate data, and the possible consequences with regard to 
clinical predictions.
Methods
receptor competition model
The receptor competition model (see Figure 1) consists of 
a set of ordinary differential equations, describing the time-
dependent competition of neurotransmitter and up to three 
different agents for a presynaptic and postsynaptic receptor, 
based on the relative affinities and concentrations of each of 
the different agents. The model runs for a maximum run time 
of 10,000 msec (10 sec). A detailed mathematical description 
of the model is given in the Appendix.
The activation of postsynaptic dopamine D2 receptor can 
be calculated based on the competition between DA and the 
different agents for both pre- and postsynaptic receptors over 
time. DA levels are determined by firing-related presynaptic 
DA release, its half-life in the synaptic cleft, and the activation 
of presynaptic D2 receptor. In addition, the model considers 
both high and low DA affinity receptor populations. All out-
comes are averages over a 10-sec timescale in which realistic 
firing patterns of burst and tonic firing are presented to the 
system (see Appendix).
The neurotransmitter is released following a user-defined 
set of firing patterns. Dopaminergic neurons tend to switch 
between low-frequency tonic firing frequencies and high-
frequency burst firing patterns.10,11
The presynaptic autoreceptor modulates the release of 
the neurotransmitter based on actual physiological processes 
and can be calibrated using experimental data on free DA. 
Because the D2 receptor uses a G-coupled protein pathway, 
a short time delay is introduced by basing the effect on 
how many receptors were bound 150 msec before release 
(see Appendix, Eq. 6). Fast cyclic voltammetry experi-
ments in rats indeed suggest that the effect of autoreceptor 
activity on DA release is complete within a few hundred 
milliseconds.6
The release dynamics can be described by a depression 
or facilitation mechanism12 (see Appendix, Eq. 7). Instead of 
using a detailed model of internal Ca++ levels to determine 
DA release, we consider the facilitation and depression of 
DA release based on the amount of time elapsed since the 
previous firing using a phenomenological equation.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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The parameters that govern presynaptic release in the 
rodent are then calibrated by correlating the effects of high 
doses of haloperidol with real-time striatal DA voltammetry 
data obtained in vivo6 and by microdialysis using D2 ago-
nists13 in the rat. We use previously published data on sulpiride 
in the marmoset to calibrate a more primatized dopaminergic 
synapse5 (see Results).
Free DA removal from the cleft is modeled by an expo-
nential decay. The decay rate is adjusted so as to correspond 
to the specific DA kinetics in various brain regions and to 
take into account the removal of DA from the cleft, not 
only via diffusion but also via transporter and/or enzyme 
mechanisms. In the striatum, DA is mostly taken up by the 
dopamine transporter (DAT) and is much less degraded by 
Catechol-O-methyl Transferase (COMT). The half-life of 
free DA from rodent striatal areas such as n. accumbens14,15 
is in the range of 30–50 msec. We further assume that the 
binding on rate for DA and the compounds is diffusion 
limited and that this depends on the size and molecular 
weight of the molecules using the Stokes–Einstein equation. 
The fraction of receptors with bound DA, tracer, drug, or 
metabolite can be calculated by solving ordinary differential 
equations that describe the binding and unbinding processes 
(see Appendix, Eqs. 1–4). We use a value of 10 nM for the 
affinity of DA for the high-affinity signal-transducing D2 
receptor.16
The simulation is initiated by running for a period of 
5 sec at the tonic firing rate of 4 Hz. The simulation then 
runs with a firing regime of 4 Hz for 2 sec, 40 Hz for 0.5 sec, 
1 Hz for 5 sec, 4 Hz for 1 sec, and 80 Hz for 0.125 sec, all 
together for 8.625 sec, based on the fact that the subcortical 
areas are usually silent and only fire in bursts when salient 
stimuli are presented.10 For calibration purposes, we apply 
the specific (artificial) firing frequencies, as outlined in the 
experimental papers.
calibration of the striatal DA receptor  
in rodents and marmosets
We calibrated the presynaptic effect on striatal   dopaminergic 
release using previously published, experimental, fast-
cyclic voltametry in vivo rodent data with high doses of the 
D2 receptor antagonist, haloperidol.6 These parameter settings 
were further verified with experimental data in wild-type 
and D3 KO mice from PD128907, a D2/D3 agonist.13 For a 
calibration on the primate striatal dopaminergic synapse, we 
used in vitro fast-cyclic voltametry data from experiments 
on marmosets.5
Rapid cyclic voltammetry was used in rats6 that were 
pretreated with RTI-76, an irreversible DAT inhibitor, to 
monitor the free caudate putamen and n. accumbens DA 
after a high dose of haloperidol (0.5 mg/kg, i.p.) and at dif-
ferent   stimulation frequencies in the ventral tegmentum area   
Facilitation
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D2 receptors
D2 receptors
Tracer
metabolite
Drug
Figure 1 general description of the striatal dopaminergic synapse and receptor competition model. The model allows user-defined presynaptic firing patterns for 
neurotransmitter release and simulates the effect of presynaptic D2 autoreceptor negative feedback on presynaptic neurotransmitter release, facilitation and depression of 
synaptic release, the decay of DA in the cleft due to diffusion, transporters and enzymes, the competition between four agents (the neurotransmitter, up to two drugs, and 
a tracer), and the dynamics of kon/koff binding of each of these agents to their respective receptors using ordinary differential equations (see Appendix) at millisecond time 
resolution. The output is the time-dependent activation level of pre- and postsynaptic dopamine D2 receptors, the fraction of each agent bound to these receptors in the 
low- and high-affinity state, as well as the concentration of free DA in the cleft.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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(10–50 Hz for 2 sec). This haloperidol concentration 
corresponds to an extremely high D2 receptor occupancy 
well above 80%; for instance, tenfold lower concentrations 
(0.04–0.08 mg/kg) correspond to clinically relevant D2 recep-
tor occupancies of 70%–80% in rodents.17 Haloperidol 
increased free DA with a maximum of ninefold increase 
over the no-haloperidol condition at 30-Hz frequency. 
  Blocking DA uptake with RTI76 ensured that only the effect 
on presynaptic D2 autoreceptors was measured. The forced 
VTA firing paradigm ensured that any feedback effect of 
D2 receptor modulation at the midbrain   dopaminergic   neurons 
was   overruled and that the resulting change in free DA in 
the striatum was almost exclusively driven by the effect of 
haloperidol on presynaptic autoreceptors.
We reproduced the outcomes of this experiment by using 
50 nM of haloperidol in the computer model (leading to over 
90% block at the D2 receptor) at different firing frequencies 
and increasing the half-life of free DA threefold to mimic the 
block of DAT. This allowed us to identify the best settings for the 
presynaptic autoreceptor-related parameters.   Figure 2A shows 
the outcome of the model and the experiment as a function of 
the firing frequency for the best parameters (Table 1).
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Figure 2 A) calibration of striatal dopaminergic synapse model in rodents (open shapes) using the experimental data (closed shapes) on the ratio of free DA levels with 
fast cyclic voltametry in vivo in the presence and the absence of high haloperidol treatment and forced dopaminergic firing and in the absence or presence of RTI-76 a potent 
DAT inhibitor.6 Using these experimental data, we calibrated the appropriate values in Appendix eq. 6 that led to the observed ratios of free DA in haloperidol treated versus 
nontreated situations in all four conditions. B) calibration of striatal dopaminergic synapse model using the experimental data in marmosets on free DA levels with fast cyclic 
voltametry in vitro and forced dopaminergic firing.5 There is an additional data point with 10-Hz firing with 1 µM of sulpiride, a specific D2 receptor antagonist. Using these 
experimental data, we calibrated the appropriate values in Appendix eq. 6 that led to the model outcomes similar to experimentally observed free DA levels.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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A different experiment in rodents documented the decrease 
of free DA in n. accumbens, measured by microdialysis, after 
application of a D2/D3 receptor agonist, PD128907.13 These 
authors reported a maximal effect of 65% decrease in free DA, 
and this effect was similar in D3 KO mice, suggesting a predomi-
nant D2 receptor mechanism. Because free DA was quantified in 
this study using the slow detection process of microdialysis, we 
used a more normal in vivo firing pattern of tonic low-frequency 
firing (1–4 Hz) interspersed with rare high-frequency bursts of 
40–80 Hz (see Methods). The reported affinity of PD128907 
for the human D2 receptor is 340 nM,18 but for the rodent D2 
receptor it is 18 nM,19 and the compound has a partial agonist 
effect of 25% relative to DA. Using the parameters derived from 
the haloperidol experiment, for a partial agonist effect of 0.25, 
the model results in a 70% decrease of free DA, comparable 
to the observed decrease of 65%.
In contrast, in marmosets, in vitro preparations of caudate 
putamen5 and application of high concentrations of sulpiride, 
a specific presynaptic D2 autoreceptor antagonist, lead to 
only a 285% increase in free DA for ventromedial striatum 
when stimulated at 10 Hz, rather than the sixfold increase 
seen in rodents at the same firing frequencies. Although 
not directly comparable, these data already suggest that the 
coupling between presynaptic D2 receptor activation and 
DA release in nonhuman primates might be lower than that 
in the rodent case. The available data on free DA after dif-
ferent firing frequencies were used to determine the best-fit 
parameters for the primate striatal dopaminergic synapse. 
This leads to a different set of calibration parameters (see 
Figure 2B and Table 1).
For a realistic set of burst and tonic firing frequencies, 
the average postsynaptic D2 receptor occupancy by DA is 
in the range of 30%–45% for the rodent calibration set and 
35%–50% for the primate calibration set. The results of the 
simulations are therefore mechanistically determined.
In the following sections, we will illustrate the conse-
quences of these differences.
interpreting radiotracer experiments
The effect of different compounds in vivo depends on the 
dose, brain penetration, and target engagement of the com-
pound. Therefore, the best way to compare the effects of com-
pounds is to normalize the concentration of the compounds 
against the apparent D2 receptor occupancy displacement of 
specific radiotracers such as 11C-raclopride and 125I-IBZM. 
Ideally, one would like to quantify the binding of a specific 
radiotracer before and after neuroleptic treatment to correct 
for any individual baseline variability of the D2 receptor. 
Although this is possible with our model, it is usually difficult 
in the clinical setting; hence, many studies define a binding 
index (Eq. 1) compared to a normal control population.
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where Am and Cerm are the specific radioactive signals in 
the region of interest, ie, in the striatum and cerebellum, 
respectively.
We used a radiotracer at a concentration of 1 pM. The 
Kd of raclopride, IBZM, and FLB457 for the D2 receptor are 
1.3 nM, 0.6 nM, and 0.018 nM, respectively.20,21 We defined 
the apparent D2 receptor occupancy as
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R
,   (2)
where Rdrug and Rcontrol are the receptor tracer occupancies, 
respectively, in the presence and the absence of the D2 recep-
tor modulator. Because the density of radioactive-sensitive 
D2 receptor binding sites is about 100-fold lower in the cer-
ebellum than that in the striatum,22 our simulations indicate 
that applying Eq. 2 results in between 1% and 1.5% error, 
compared to the correct use of Eq. 1 (data not shown).
Figure 3 shows the effect of different radiotracers on 
the calculated receptor occupancy for a range of haloperi-
dol doses. The observation that the calculated D2 receptor 
occupancy level decreases when higher-affinity tracers are 
Table 1 Different parameters for fitting the striatal dopaminergic 
synapse to experimental rodent and primate data suggest that 
presynaptic  autoreceptor  coupling  to  dopaminergic  release 
is weaker in the primate case, as well in absolute size as in the 
extent of temporal relationship
Parameter Calibration 
rodent
Calibration  
primate
Note
relScale 1 0.95 Maximum increase  
due to presynaptic  
D2 autoreceptor
relSens 1.95 0.85 Amplification factor 
for presynaptic D2 
autoreceptor effect
normBound 950 370 Amount of normal 
presynaptic D2 binding 
before release
Facilitation  
size
2 0.9 Size of the coupled 
facilitation
Facilitation 
half-life
400 msec 90 msec half-life of the 
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used is in line with reported differences between apparent 
receptor occupancy measured with raclopride and IBZM in 
the same subjects.23 This can be partially explained by the 
fact that the greater the affinity a tracer has for a receptor, 
the more difficult it is for the drug to compete with it and 
dislodge it.
Results
effect of partial agonists and full 
antagonists on functional postsynaptic  
D2 receptor activation
In order to compare the effect of partial agonists with full 
antagonists on postsynaptic receptor physiology, we introduce 
the concept of functional D2 receptor antagonism, FA. This is 
calculated as the reduced postsynaptic D2 receptor activation, 
normalized to the no-drug situation:
 
FA
Act
Act
drug
control
=−

 

  100 1,   (3)
where Actdrug and Actcontrol are actual postsynaptic D2 receptor acti-
vation levels in the presence and absence of drug, respectively.
These functional antagonist levels reflect the complex 
consequences of both an indirect effect of the partial agonist 
on presynaptic D2 receptor-mediated DA release and its direct 
effect on inhibiting the postsynaptic receptor. The rationale 
for using partial agonists in schizophrenia is partly based on 
the experimental observation that stimulating presynaptic D2 
autoreceptors reduces free DA release, which is functionally 
equivalent to a postsynaptic D2 receptor block. In addition, 
a partial agonist at the postsynaptic receptor can compete 
with endogenous DA (a full agonist) to reduce the activa-
tion level. As these two processes require vastly different 
degrees of partial agonism, the ideal profile is a balance 
of affinity for the pre- and postsynaptic receptor and the 
degree of partial activation. We will now compare the effect 
of aripiprazole and bifeprunox on functional postsynaptic 
D2 receptor antagonism in function of the tracer-reported 
D2 receptor occupancy.
A recent study7 reports a low partial agonism for aripip-
razole (25%), whereas the affinity of aripiprazole for both 
pre- and postsynaptic receptors is identical (Kd of 7.1 nM). 
To further complicate matters, in humans, the major 
metabolite dehydro-aripiprazole OPC14857 has a lower 
partial agonist effect (18% maximal effect) and a higher 
affinity (Kd = 3.5 nM); whereas, the major rat metabolite 
4-hydrox-phenylpiperazine DM1451 is a full antagonist at 
the rodent receptor with a Kd of 1.5 nM.24 In humans, this 
metabolite contributes to between 25% and 40% of the active 
moiety.25 We assume an identical level of the metabolite in 
rodents.
We simulated the effect of bifeprunox versus the active 
moiety of aripiprazole in comparison to haloperidol on the 
functional antagonism dose–responses under primate cali-
bration parameters (Figure 4A). Bifeprunox has a slightly 
higher partial agonist effect (range 27%–35%, average 31%) 
than aripiprazole (average 25%).7,26–28 We also indicated the 
postsynaptic D2 receptor antagonism of 4 mg haloperidol 
(corresponding to 65% D2 receptor occupancy), a dose which 
is known to have a minimal antipsychotic effect. The model-
ing results suggest that the dose–response of haloperidol is 
steeper than that of both partial agonists. In addition, only 
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Figure 4 A) Functional antagonism (ie, the normalized decrease in actual D2 receptor activation) for different doses of haloperidol, bifeprunox, and the active moiety 
of aripiprazole and OPc-14857 using primate-derived calibration parameters. The x-axis (dose) is expressed as measured D2 receptor occupancy in a positron emission 
tomography (PeT) tracer imaging experiment with raclopride for each drug. The clinically relevant functional antagonism corresponding to a 4-mg haloperidol dose of 
about 52% is indicated by the horizontal line. The data suggest that the dose–response of the partial agonists is not as pronounced as haloperidol’s dose response and that 
aripiprazole at the highest dose, but not bifeprunox, can achieve D2 receptor functional antagonist levels comparable to clinically active levels of haloperidol. B) Functional 
antagonism at the postsynaptic D2 receptor of hypothetical partial agonists with the same 7.1 nM Kd for the D2 receptor as aripiprazole but with different maximal agonists 
effects (0%–35%) in a firing frequency paradigm similar to an in vivo situation. The x-axis is expressed as the apparent D2 receptor occupancy measured with raclopride for 
each hypothetical molecule. A 4-mg haloperidol dose corresponds to a functional D2 receptor antagonism of about 52% (the horizontal line). The figure suggests that there 
is only a limited degree of partial agonism (0%–25%) that results in sufficient functional D2 receptor antagonism at the highest achievable dose. C) comparison of functional 
postsynaptic D2 receptor antagonism between the relevant active moiety of aripiprazole and bifeprunox using both rodent and primate calibration parameters. The major 
human metabolite of aripiprazole is a partial agonist with a Kd of 3.5 nM and a maximal effect of 18%, while the rodent metabolite is a full antagonist with a Kd of 1.9 nM; both 
of them account for 25% of the active moiety. The functional postsynaptic D2 receptor antagonism is plotted against the apparent D2 receptor occupancy measured with 
raclopride. The data suggest that for the rodent case, bifeprunox is superior to the active moiety of aripiprazole, while the opposite is true for the primate situation, where 
bifeprunox does not achieve the same functional D2 receptor antagonism with 4 mg haloperidol.
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the active human moiety of aripiprazole at the highest doses 
achieves a postsynaptic D2 receptor antagonism comparable 
to haloperidol at 70% D2 receptor occupancy. Bifeprunox 
fails to reach the minimum level of functional postsynaptic D2 
receptor antagonism, corresponding to 4 mg haloperidol, at 
any dose likely because in the primate dopaminergic synapse 
there is a smaller effect on presynaptic DA release so that 
the increased partial agonism of bifeprunox doesn’t pay off 
presynaptically and ends up hurting more postsynaptically.
Balance of pre- and postsynaptic effect  
of partial agonists
The previous data suggest that the balance of pre- and post-
synaptic effects is critical to achieve sufficient postsynaptic 
functional D2 receptor antagonism. We simulated the effects 
of hypothetical analogs of a partial agonist with the same high 
affinity as that of aripiprazole (7.1 nM) for the D2 receptor 
but with different degrees of partial agonism (equal at both 
the pre- and postsynaptic receptors) in a dopaminergic syn-
apse calibrated with the primate parameter set. Figure 4B 
suggests that there is an optimal window of partial agonism 
(,25%) that can result in sufficient functional D2 receptor 
antagonism similar to clinically relevant doses of haloperi-
dol. This can account for the balance between presynaptic 
autoreceptor activation and postsynaptic competition with 
endogenous DA. Note that for higher levels of partial ago-
nism, an increasingly higher dose is needed. However, for a 
partial agonist with a maximal effect .30%, the functional 
antagonism at the postsynaptic D2 receptor never gets in the 
range of 4-mg-haloperidol-induced functional postsynaptic 
D2 receptor antagonism.
consequence of rodent and primate 
settings for partial agonists
We further illustrate the difference between rodent and 
primate parameter settings by comparing bifeprunox and 
the active moiety of aripiprazole in dopaminergic synapses 
in rodent synapses. As mentioned above, they do have a 
similar affinity26–28 for the D2 receptor (a Kd of 1.9 nM for 
bifeprunox and 7.1 nM for aripiprazole), but the functional 
activity of bifeprunox is slightly higher than partial agonism 
(36% versus 25%).7 In addition, the major rat metabolite of 
aripiprazole, DM-1457, is a potent full D2 receptor antagonist 
with a fivefold higher affinity and accounts for about 25% 
of the active moiety.
In vivo preclinical animal studies suggest that bifeprunox 
is at least as active as, if not more active than, aripiprazole,9 
whereas the clinical efficacy of bifeprunox in schizophrenia 
is substantially lower.6 We used our receptor competition 
model to address the difference of these compounds in the 
rodent animal models and the primate setting.
Figure 4C shows the functional antagonism for rodent 
versus primate calibration parameters. The model outcome 
suggests that in terms of functional postsynaptic D2 receptor 
antagonism, bifeprunox outperforms the active moiety of 
aripiprazole under rodent calibration settings, but that the 
opposite is true for the primate settings. The major human 
metabolite of aripiprazole has a somewhat lower maximal 
partial receptor effect than the parent molecule, ensuring 
that the active moiety is well within the range of sufficient 
postsynaptic D2 receptor antagonism for the primate calibra-
tion setting (see Figure 4B), whereas the full antagonism of 
the rodent metabolite tends to raise inadvertently presynaptic 
DA levels in the rodent calibration setting.
Recently new data suggest that aripiprazole is a full 
antagonist in cell systems expressing the long isoform, 
D2L.29 As D2L is likely the postsynaptic D2 receptor,30 this 
would even increase the level of functional antagonism at 
the postsynaptic D2 receptor (data not shown). However, 
in the absence of similar data for bifeprunox, we wanted to 
limit our analysis to two very similar agents with similar 
pharmacology and explore the parameter space of a partial 
agonist that would lead to a robust postsynaptic functional 
D2 receptor antagonism.
correlation with the clinical situation
Because the calibration conditions for rodent and primate 
were determined in different conditions, we next addressed 
the question “How will the two calibration sets compare 
to the clinical situation?” We therefore simulated the four 
clinical doses of aripipirazole and the three clinical doses of 
bifeprunox together with the reference drug haloperidol at 
4 mg in the computer model with both calibration sets and 
compared the outcome to the reported clinical effects on the 
Positive and Negative Syndrome Scale (PANSS) total scale. 
The actual compound concentrations for all the conditions 
were determined by simulating the reported positron emis-
sion tomography (PET) imaging displacement studies with 
raclopride.
In stable treatment-responsive patients who were switched 
from other antipsychotics, it was reported that a dose of 
5 mg aripiprazole resulted in a PANSS total improvement 
of 9.4 points,31 whereas a dose of 15 mg,32,33 20 mg,34,35 
and 30 mg33,35,36 improved the PANSS total by 15.5 points, Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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14.5 points, and 12.6 points, respectively. These doses cor-
responded to receptor occupancies of 83%, 91%, 95%, 
and 97%, respectively.37,38 Similarly, the improvements for 
bifeprunox on the PANSS total in a 6-week study were 
reported to be 9.7 points, 5 points, and 11.3 points with 5 mg, 
10 mg, and 20 mg of bifeprunox, respectively.6 Unfortunately, 
no PET imaging data are publicly available for bifeprunox; 
however, from the reported clinical data and side effects,6 we 
inferred that bifeprunox readily crossed the blood–brain bar-
rier and results in receptor occupancies of 80% and above.
The clinical data for 4 mg haloperidol were derived as 
weighted averages from 4 studies covering 623 patients.39–42 
Actual haloperidol concentration for this dose was simulated 
to be 70% using the reported PET displacement studies with 
raclopride.43–45
Figure 5 shows the correlation between the clinical 
outcomes (improvement in PANSS total), the postsynaptic 
functional D2 receptor antagonism, and the primate calibra-
tion sets. The primate calibration sets result in a correlation 
of r2 = 0.601 or r = 0.77 (P = 0.016), while a correlation 
coefficient of r2 = 0.023 or r = 0.15 (P = 0.70) is obtained 
using the D2 receptor occupancy as independent variable 
and a correlation of r2 = 0.237 or r = −0.45 (P = 0.20) when 
using the functional postsynaptic D2 receptor antagonism 
calibrated with rodent data, suggesting that the computer 
model with the primate calibration set is able to explain 
much more of the variance. Moreover, the correlation with 
the rodent   calibration set would lead to a negative slope, 
ie, more clinical efficacy with lower postsynaptic D2   receptor 
antagonism. This is clearly not in line with the clinical 
observations.
Discussion
The actual competition among the neurotransmitter, the 
tracer, the drug, and the active drug metabolite in a typical 
CNS synapse for a receptor binding site is complex and hard 
to understand quantitatively without systematic computer 
modeling. Neurotransmitters are released in well-defined 
firing patterns, and their release is modulated by presynap-
tic autoreceptor activation. Time-dependent facilitation and 
depression can further alter the quantity of neurotransmitter 
released, while the dynamics of free neurotransmitter in 
the synapse are determined by transporters, diffusion, and 
catabolic enzymes. The ability to quantitatively simulate the 
interactions between different physicochemical processes is 
one of the main arguments for this approach of computer 
modeling.
This report describes a computer model and its calibration 
and application to the striatal dopaminergic synapse. As our 
objective was to compare partial agonists with full antago-
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(5 mg, 10 mg, and 20 mg) and the functional postsynaptic D2 receptor antagonism in the dopaminergic synapse computer model with primate calibration. The y-axis value for 
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nists, we introduced the concept of functional D2 receptor 
antagonism at the postsynaptic D2 receptor. This is calculated 
as the reduction in receptor activation, normalized to the 
no-drug situation. Interestingly, for a full antagonist, this 
functional D2 receptor antagonism, although proportional 
to the D2 receptor occupancy level calculated from the 
imaging experiments, is somewhat smaller and reflects the 
complex interaction between the drug and the endogenous 
neurotransmitter in such a synapse. For instance, inhibition 
of the presynaptic receptor by a full antagonist leads to an 
increase in the release of free DA, thereby countering its 
effect at the postsynaptic receptor.
The model has been calibrated using published experi-
mental data that quantified the strength of presynaptic DA 
receptor feedback on DA release with high concentrations of 
dopamine D2 receptor antagonists and forced firing frequen-
cies of dopaminergic neurons in rodents6 or in primates.5 Both 
calibration sets lead to an average D2 receptor occupancy by 
endogenous DA in drug-free conditions between 30% and 
50%, with the primate data being slightly higher. This is in 
the experimental range observed in humans,46 baboons,22 and 
rodents.47 In primates at least, the experimental data suggest 
that the effect of presynaptic receptor coupling to DA release 
is substantially lesser, leading to a different dose dependency 
of a partial agonist on the functional postsynaptic D2 recep-
tor antagonism.
Marmosets are increasingly being used for biomedical 
research; their usefulness is likely to be limited as they can 
differ quite substantially from old-world primates.48 How-
ever, they have characteristic anthropoid primate traits. It is 
of interest to note that similar measurements in striatal slices 
of squirrel monkeys result in low DA levels that are at least 
in qualitative agreement with data from the marmoset.49
Although we don’t have similar data for the human situa-
tion, such disconnect between rodent and primate physiology 
suggests that extrapolations from preclinical rodent models 
to the human clinical situation need to proceed cautiously.
Interestingly, the model outcome suggests that the calcu-
lated D2 receptor occupancy from a PET imaging study can 
be different when different radiotracers are used in the same 
patient treated with antipsychotic medication. This is in line 
with reported clinical data that systematic lower occupancy 
readout was found with IBZM when compared to raclopride 
for all subjects and brain regions in the same schizophrenia 
patients.23 The authors concluded that the reasons for the 
radiotracer differences were due to the degradation by high-
energy photons in the IBZM images, but that they were not 
due to the choice of reference region or the assumption of 
pseudo-equilibrium. Our results suggest that the differential 
competition among the tracer, the neurotransmitter, and the 
drug at the level of the binding site can contribute additionally 
to this difference. Failure to appreciate this effect can lead to 
misinterpretation with regard to receptor occupancies when 
using different radiotracers. Fortunately, the large majority 
of clinical imaging studies with antipsychotics have been 
performed with the same radiotracer, raclopride, making 
comparisons between drugs easier.
Partial D2 receptor agonists are an interesting option to 
achieve functional D2 receptor inhibition, because they tend 
to reduce the amount of presynaptic DA released by stimulat-
ing the negative-feedback D2 autoreceptor. These drugs are 
supposed to act more closely to the actual   pathology as recent 
imaging studies in an at-risk for mental state cohorts suggests 
a presynaptic pathology in schizophrenia patients.4 The differ-
ences in calibration of this presynaptic effect also suggest that 
partial agonists in the rodent calibration will lead to greater 
functional postsynaptic antagonism, as compared to the 
primate calibration setting, because they reduce the levels of 
released DA more strongly. This might lead to an overestima-
tion of the effect of partial agonists in rodent models.
It is important to note that the model outcome is presented 
as the level of postsynaptic D2 receptor activation and does 
not take into account any further physiological intracellular 
effect or pathway activation. Recently, the concept of func-
tional selectivity has been proposed to account for some of 
the in vivo effects of aripiprazole.29 The aripiprazole effect 
can range from partial agonism to full antagonism, depending 
on the cell system, the latter mostly in cell systems overex-
pressing human D2L receptors. These D2L receptors are most 
likely located postsynaptically,30 and an antagonistic effect of 
aripiprazole can therefore explain the clinical observations of 
worsening motor symptoms in the treatment of patients with 
Parkinson’s.50 Substituting the partial agonist effect of arip-
iprazole at the postsynaptic D2 receptor by a full antagonist 
effect will increase the functional postsynaptic D2 receptor 
antagonism, as free DA is now replaced by a compound 
that, rather than partially activating, completely blocks the 
receptor, whereas the partial agonist effect at the presynaptic 
receptor continues to reduce levels of released DA.
The simulation further suggests that D2 receptor func-
tional antagonism of the active moiety of aripiprazole at high 
D2 receptor occupancy levels (.90%) can achieve similar lev-
els as clinically relevant doses of haloperidol. We compared 
the effects of the partial agonists on postsynaptic D2 receptor 
antagonism in the presence of 4 mg haloperidol. Although 
often higher doses are used in clinical practice, a 4-mg dose Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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gives the minimal clinical benefit43 and is therefore a good 
benchmark. Although the   pharmacology of both   aripiprazole 
and bifeprunox is quite complex, including effects on other 
dopaminergic, serotonergic, and noradrenergic receptors,29 
functional postsynaptic D2 receptor antagonism drives a 
substantial part of the clinical response.8 The fact that high 
doses are needed is in line with the reported proportional 
dose–response for aripiprazole in clinical trials,35,36 with 
clinically efficacious doses that correspond to .95% D2 
receptor occupancy.37
The model simulations further suggest that there is a 
limited therapeutic window for partial agonists, because of 
the delicate balance between pre- and postsynaptic effects. 
  Having too strong an affinity and maximal agonist effect 
might indeed lead to a lower postsynaptic inhibition that out-
weighs the benefits of presynaptic D2 receptor stimulation.
Such computer models can help to better extrapolate find-
ings from preclinical rodent models to the clinical situation. 
Because of the stronger coupling of presynaptic D2 autorecep-
tor to DA release in the rodent case, bifeprunox outperforms 
the active moiety of aripiprazole, a result observed experi-
mentally in preclinical rodent models.9 In contrast, the model 
predicts a superiority of the active   moiety of   aripiprazole in 
primate conditions, which is partially due to the   different 
pharmacological activities of its major   metabolite24 and par-
tially due to the lower coupling of presynaptic D2 autoreceptor 
activation to subsequent DA release.5 The results of the model 
suggest that aripiprazole has a substantial clinical advantage 
over bifeprunox at least in functional D2 receptor antagonism. 
Obviously, it is possible that   clinical efficacy is also driven by 
other processes as   discussed above, but it is of interest to note 
that the bifeprunox clinical effect on PANSS total is limited6 
to the point that the clinical development of the compound 
has been halted.
In this study, we assumed that, unlike aripiprazole, 
bifeprunox has no major active metabolite in the human/
primate or the rodent situation, as there are no published 
data on such a metabolite. It could still be the case that 
human metabolites of bifeprunox, if present, could have 
a pharmacological activity that is sufficiently different to 
change dramatically the functional D2 receptor antagonism. 
Notwithstanding this, the data illustrate the power of the 
model to assess the effect of unique human metabolites.
As with any model, there are limitations on this specific 
modeling approach. Because we don’t take into account spa-
tial dimensions, we assume that all of the agents have perfect 
access to each other. This could lead to an overestimation 
of the amount of bound receptors. However, in terms of 
understanding the relative effects, such as inhibition fraction, 
we expect the model to behave reasonably well. Because we 
are dealing with synaptic effects where the distance between 
the membranes is very small, there is also a greater prob-
ability that the different agents will come into contact with a 
  receptor, making it more similar to the well-mixed solution 
that the equations describe.
Although the model is based on biological   properties 
of the dopaminergic synapse (using realistic values for 
DA dynamics), some of the relations, for instance those 
between presynaptic dopamine D2 autoreceptor and 
DA release after stimulation, are introduced in a phenom-
enogical, rather than an exact biological, way. The biology 
of presynaptic DA release is quite complex, and there are 
still many unresolved issues (for a complex computational 
model see Qi et al51). This particular computational model 
has focused on the biochemistry of processes we have mod-
eled in a phenomenological way but calibrated using actual 
experimental data with a limited set of parameters. In con-
trast to rodent data, the primate values are measured from 
ex vivo preparations5 that obviously might lack a number of 
physiological processes that are active in vivo. However, the 
relative effect and the dose–response for the active moiety of 
aripiprazole with primate parameters corresponds to observed 
clinical effects, again assuming that the D2 receptor block 
drives most of the clinical outcome.8,52
Unlike other models dealing with the interpretation of 
PET imaging22 that simulate the binding kinetics of tracers 
over many minutes, our model takes into account detailed 
physiological processes on a millisecond timescale.
We anticipate that this method becomes even more 
  valuable in the cases where simple occupancy rules/  formulae 
do not apply in conditions such as (1) in the absence of 
  tracers, (2) with multiple drugs (and metabolites) acting on 
the same receptor, (3) when dealing with partial agonists, and 
(4) when the rodent physiology is different from the human 
physiology. In principle, such a generic receptor competi-
tion model could also be applied to different CNS synapses, 
such as cortical DA synapses or serotonergic synapses, using 
appropriate affinity and physiology parameters.
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Appendix
Here, we present a more detailed description of the receptor 
competition model.
Dynamical binding and unbinding of the different agents 
to the receptor sites are calculated as follows. If [dop] is 
the free DA concentration and [Df] is the concentration of 
free receptors, then the change in receptors bound by DA, 
[Dn], is governed by the following ordinary differential 
equation (ODE):
 
∂
∂
=× ×− ××
[]
[] [] [] ,
D
t
kD kKD n
on
n
fo n
n
d
n
n dop   (1)
with the initial condition that all receptors begin in the 
free state. With sub- and superscripts n, d, m, and t 
referring to neurotransmitter DA, drug, metabolite, and 
tracer, respectively, the change in receptors for drug, 
metabolite, and tracer binding is governed by the following 
coupled ODEs:
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Alternatively, the metabolite can be substituted by a 
second drug in simulation of polypharmacy. We assume 
that the association to the receptor is diffusion limited, 
  giving us a value for the forward binding rate constant 
kon of 140–150 µM−1 sec−1 for a molecule with MW in 
the range of 200–400 (as an example for the case of 
Ach53). In general, Kd = koff  /kon so that Koff = Kd × Kon. 
Furthermore,
 
DDDDDD fondmt =−−−− ,  (5)
where Do is the concentration of receptors. All differential 
equations are solved with a fourth-order Runge–Kutta 
method with a time step of 0.01 msec.
The amount of free DA depends on two processes, 
exponential decay and quantal release. Exponential decay 
is classically defined as  dop exp  ln 2h alf-life [] =− ( ) ( ) () tt , 
where half-life is the half-life of the decay process. At times 
of release, [dop] is immediately updated by adding the release 
amount.
The amount of presynaptic receptor activation which 
occurred 150 msec before the current release event then 
determines the amount of new release as follows
releaser elease relScale
recAct
recAct
new
relSens
rel
= +



× −
0 1
12 S Sens relSens normBound +

 

 


 ,  
(6)
where release0 is the base release amount, relScale is the 
maximum relative change for release, recAct is the actual 
presynaptic receptor activation 150 msec earlier, relSens 
is the sensitivity to the presynaptic receptor (lower values 
create a shallow response and higher values create a sharp 
difference between activation levels), and normBound is 
the amount of normal presynaptic binding that one would 
expect in the tonic case (ie, when recAct equals normBound, 
the new release equals the baseline release amount). The 
dynamical independent variable recAct is calculated from 
earlier time points and is initiated using a run-in time period 
of 4 sec. We calibrate the parameters so that the coupling 
of presynaptic D2 receptor activation to DA release reflects 
actual experimental data (as seen in Results).
In addition, the release can be modulated by a depression 
or facilitation mechanism.12 Instead of using internal Ca++ 
levels to determine DA release, we consider the facilitation 
and depression of DA release based solely on the amount of 
time elapsed since the previous firing using a simple transfer 
equation. Thus, the amount of DA released is based both on 
the history of firing and the activation level of the presynaptic 
D2 autoreceptors. If we denote the time of the nth firing by tn, 
then the release amount is modified based on all previous 
firings as follows
 
releaser elease newf f
dd
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−−
−
1
1
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=1 i
n
ni kt t w
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exp( () , tt ni −    

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(7)
where wf is the facilitation weight, wd is the depression 
weight, kf is the decay rate of facilitation, and kd is the decay Neuropsychiatric Disease and Treatment
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rate of depression. These four parameters will be calibrated 
to experimental data.
The simulation is initiated by first finding the equilib-
rium, given a constant amount of free DA at 500 nM. The 
simulation is then run for a transitory time of 5 sec at the 
tonic firing rate of 4 Hz. Finally, the simulation runs for an 
additional 2.5 sec during which time average binding levels 
are determined and then the simulation runs with the pre-
defined firing pattern.